Act now in patients with elevated Lp(a)

Act now to reduce cardiovascular (CV) risk in patients with elevated Lp(a), and don’t delay until results of Lp(a) lowering outcome trials are available. This was the key message from Professor Florian Kronenberg, from the Medical University of Innsbruck, Austria, in his wide-ranging review of ongoing Lp(a) outcomes trials and the importance of addressing traditional CV risk factors, including in primary prevention populations.¹